The Role of Kallikrein10 (KLK10) Polymorphism in Prostate Cancer Susceptibility

Urol J. 2021 May 26;19(1):41-44. doi: 10.22037/uj.v18i.6425.

Abstract

Purpose: The present study aims to investigate the potential role of Kallikrein 10 (KLK10) genotype and allele frequencies in predisposition to prostate cancer.

Materials and methods: KLK10 (rs7259451) gene polymorphisms were determined by real-time polymerase chain reaction analysis in patients with prostate cancer (n=69) and controls (n=76).

Results: KLK10 gene frequencies were significantly different in the case and control groups (P = .028). GG carriers were significantly higher in the control group (P = .034), whereas TT carriers were higher in the prostate cancer group (P = .033). Furthermore, The patients with GG genotype had the lowest PSA levels while TT carriers had the highest (P = .005).

Conclusion: According to the results, we suggested that carrying variant T allele and also carrying homozygote TT genotype could be a potential risk, while ancestral homozygote GG genotype and G allele are risk reducing factors for prostate cancer.

MeSH terms

  • Alleles
  • Case-Control Studies
  • Gene Frequency
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Kallikreins* / genetics
  • Male
  • Polymorphism, Single Nucleotide
  • Prostatic Neoplasms* / genetics

Substances

  • KLK10 protein, human
  • Kallikreins